Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce re...

Descripción completa

Detalles Bibliográficos
Autores principales: Procházka, Vít, Belada, David, Janíková, Andrea, Benešová, Kateřina, Mociková, Heidi, Ďuraš, Juraj, Pirnos, Jan, Kopečková, Kateřina, Campr, Vít, Fürst, Tomáš, Pytlík, Robert, Sýkorová, Alice, Michalka, Jozef, Dlouhá, Jitka, Papajík, Tomáš, Trněný, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175682/
https://www.ncbi.nlm.nih.gov/pubmed/35847728
http://dx.doi.org/10.1002/jha2.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175682/
https://www.ncbi.nlm.nih.gov/pubmed/35847728
http://dx.doi.org/10.1002/jha2.60

Ejemplares similares